Q3 2021 Targovax ASA Earnings Call Transcript
Welcome to Targovax and our report and presentation of our third quarter results. My name is Erik Digman Wiklund, and I was recently appointed CEO of Targovax.
So first of all, let me remind you of who we are and what we do. We are a Norway-based immuno-oncology biotech, and our focus is on developing immune activators. Our lead product candidate is called ONCOS-102. And this is a novel immune activator, which has demonstrated clinical efficacy in several hard-to-treat solid tumors. We have confirmed the mode of action of ONCOS-102 in a clinical setting and demonstrated broad and powerful immune responses that makes ONCOS-102 a very attractive combination partner for other immunotherapies in difficult to treat solid tumors.
We are currently preparing for the next steps of our development program, which will be a PD-1 refractory melanoma in a broader platform trial where we are going to assess multiple combinations in parallel. ONCOS-102 is protected by both method of use and composition of matter patents, and we have orphan drug designation in 3
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
